Cargando…

Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor

In this study, we report the β(1)‐adrenoceptor binding kinetics of several clinically relevant β(1/2)‐adrenoceptor (β(1/2)AR) agonists and antagonists. [(3)H]‐DHA was used to label CHO‐β(1)AR for binding studies. The kinetics of ligand binding was assessed using a competition association binding met...

Descripción completa

Detalles Bibliográficos
Autores principales: Sykes, David A., Jiménez‐Rosés, Mireia, Reilly, John, Fairhurst, Robin A., Charlton, Steven J., Veprintsev, Dmitry B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237807/
https://www.ncbi.nlm.nih.gov/pubmed/35762357
http://dx.doi.org/10.1002/prp2.978
_version_ 1784736886479126528
author Sykes, David A.
Jiménez‐Rosés, Mireia
Reilly, John
Fairhurst, Robin A.
Charlton, Steven J.
Veprintsev, Dmitry B.
author_facet Sykes, David A.
Jiménez‐Rosés, Mireia
Reilly, John
Fairhurst, Robin A.
Charlton, Steven J.
Veprintsev, Dmitry B.
author_sort Sykes, David A.
collection PubMed
description In this study, we report the β(1)‐adrenoceptor binding kinetics of several clinically relevant β(1/2)‐adrenoceptor (β(1/2)AR) agonists and antagonists. [(3)H]‐DHA was used to label CHO‐β(1)AR for binding studies. The kinetics of ligand binding was assessed using a competition association binding method. Ligand physicochemical properties, including logD(7.4) and the immobilized artificial membrane partition coefficient (K (IAM)), were assessed using column‐based methods. Protein Data Bank (PDB) structures and hydrophobic and electrostatic surface maps were constructed in PyMOL. We demonstrate that the hydrophobic properties of a molecule directly affect its kinetic association rate (k (on)) and affinity for the β(1)AR. In contrast to our findings at the β(2)‐adrenoceptor, K (IAM), reflecting both hydrophobic and electrostatic interactions of the drug with the charged surface of biological membranes, was no better predictor than simple hydrophobicity measurements such as clogP or logD(7.4), at predicting association rate. Bisoprolol proved kinetically selective for the β(1)AR subtype, dissociating 50 times slower and partly explaining its higher measured affinity for the β(1)AR. We speculate that the association of positively charged ligands at the β(1)AR is curtailed somewhat by its predominantly neutral/positive charged extracellular surface. Consequently, hydrophobic interactions in the ligand‐binding pocket dominate the kinetics of ligand binding. In comparison at the β(2)AR, a combination of hydrophobicity and negative charge attracts basic, positively charged ligands to the receptor's surface promoting the kinetics of ligand binding. Additionally, we reveal the potential role kinetics plays in the on‐target and off‐target pharmacology of clinically used β‐blockers.
format Online
Article
Text
id pubmed-9237807
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92378072022-06-30 Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor Sykes, David A. Jiménez‐Rosés, Mireia Reilly, John Fairhurst, Robin A. Charlton, Steven J. Veprintsev, Dmitry B. Pharmacol Res Perspect Original Articles In this study, we report the β(1)‐adrenoceptor binding kinetics of several clinically relevant β(1/2)‐adrenoceptor (β(1/2)AR) agonists and antagonists. [(3)H]‐DHA was used to label CHO‐β(1)AR for binding studies. The kinetics of ligand binding was assessed using a competition association binding method. Ligand physicochemical properties, including logD(7.4) and the immobilized artificial membrane partition coefficient (K (IAM)), were assessed using column‐based methods. Protein Data Bank (PDB) structures and hydrophobic and electrostatic surface maps were constructed in PyMOL. We demonstrate that the hydrophobic properties of a molecule directly affect its kinetic association rate (k (on)) and affinity for the β(1)AR. In contrast to our findings at the β(2)‐adrenoceptor, K (IAM), reflecting both hydrophobic and electrostatic interactions of the drug with the charged surface of biological membranes, was no better predictor than simple hydrophobicity measurements such as clogP or logD(7.4), at predicting association rate. Bisoprolol proved kinetically selective for the β(1)AR subtype, dissociating 50 times slower and partly explaining its higher measured affinity for the β(1)AR. We speculate that the association of positively charged ligands at the β(1)AR is curtailed somewhat by its predominantly neutral/positive charged extracellular surface. Consequently, hydrophobic interactions in the ligand‐binding pocket dominate the kinetics of ligand binding. In comparison at the β(2)AR, a combination of hydrophobicity and negative charge attracts basic, positively charged ligands to the receptor's surface promoting the kinetics of ligand binding. Additionally, we reveal the potential role kinetics plays in the on‐target and off‐target pharmacology of clinically used β‐blockers. John Wiley and Sons Inc. 2022-06-28 /pmc/articles/PMC9237807/ /pubmed/35762357 http://dx.doi.org/10.1002/prp2.978 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Sykes, David A.
Jiménez‐Rosés, Mireia
Reilly, John
Fairhurst, Robin A.
Charlton, Steven J.
Veprintsev, Dmitry B.
Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title_full Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title_fullStr Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title_full_unstemmed Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title_short Exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
title_sort exploring the kinetic selectivity of drugs targeting the β(1)‐adrenoceptor
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237807/
https://www.ncbi.nlm.nih.gov/pubmed/35762357
http://dx.doi.org/10.1002/prp2.978
work_keys_str_mv AT sykesdavida exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor
AT jimenezrosesmireia exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor
AT reillyjohn exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor
AT fairhurstrobina exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor
AT charltonstevenj exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor
AT veprintsevdmitryb exploringthekineticselectivityofdrugstargetingtheb1adrenoceptor